Gene Therapy in a Nonhuman Primate Model of Parkinson's Disease

Abstract

In the final year of this grant, we are completgeing an experiment in which aged monkeys are assessed for levodopa-induced dyskinesias and given a fluorodopa PET scan. They then receive lenti-ODNF under the control of the tetracycline promoter. Three months following lenti-ODNF, they are again assessed for levodopa-induced dyskinesias and given a fluorodopa PET scan. Then half of the aged monkeys receive tetracycline to shut of the GDNF expression in vivo. Monkeys are assessed for levodopa-induced dyskinesias and given a fluorodopa PET scan 3 and 6 months later. This study will determine whether we can control gene expression in vivo and make gene therapy safe for clinical use.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2002
Accession Number
ADA417090

Entities

People

  • Jeffrey H. Kordower

Organizations

  • Rush University Medical Center

Tags

DTIC Thesaurus Topics

  • Anti-Bacterial Agents
  • Brain
  • Diseases And Disorders
  • Gene Expression
  • Gene Therapy
  • Medical Personnel
  • Movement Disorders
  • Neurodegeneration
  • Neurons
  • Neurosciences
  • Parkinson'S Disease
  • Surgery
  • Therapy
  • Tyrosine
  • Virotherapy

Fields of Study

  • Medicine

Readers

  • Neurodegenerative Parkinson's Disease and Rickettsial Disease handbook, including the data level of dopamine, BC, neurons, and PD.
  • Neuroscience
  • Oncology

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech